103980-44-5

Product Details:

CasNo： 103980-44-5

Molecular Formula： C19H18ClN5O7S3

Purity： 99%

Synonyms: CEFTIOFUR HCL; U-67279A; (6r-(6alpha,7beta(z))-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((2-furanylcarbonyl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrochloride; (6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-[[(2-furanylcarbonyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid,7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((2-furanylcarbonyl)thio)methyl)-8-oxo,monohydrochloride,(6R,7R)

Melting point: >190°C (dec.)

Boiling point: 814.1ºC at 760 mmHg

Alpha: -92～-98° (D/20℃) (c=0.2, CH3OH)

Solubility: DMSO (Slightly), Methanol (Slightly)

Form: Solid

Color: Off-White

Description:

Ceftiofur Hydrochloride is the hydrochloride salt form of ceftiofur, a semisynthetic, beta-lactamase-stable, broad-spectrum, third-generation cephalosporin with antibacterial activity. Ceftiofur binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.

Uses:

An antibacterial.

Ceftiofur hydrochloride is used for the treatment and control of infections in cattle and pigs caused by susceptible pathogens.  It is approved for the treatment of bovine respiratory disease caused by Bartonella mansoni, Bartonella multocida and Bartonella somniferum (formerly Bartonella somniferum).
Ceftiofur hydrochloride is also used for the treatment of bovine interdigital necrotizing bacillosis (rotten foot disease) caused by Fusobacterium necrophorum or Bacteroides melaninogenicus. Ceftiofur hydrochloride has been shown to be effective at a dose of 2.2 mg/kg for the treatment of acute postpartum onychomycosis in dairy cows or by intrauterine instillation (1 g) for the treatment of retained foetal membranes.
Ceftiofur hydrochloride can be used for the treatment of SRD caused by Actinobacillus, Plasmodium multocida, Salmonella cholera and Streptococcus suis. Ceftiofur hydrochloride and ceftiofur amorphous acid can also be administered via the intra-udder route in dairy cows. For intramammary use, a specific formulation (Spectramast DC) is recommended.